Drugs in development for Parkinson's disease: An update

Current Opinion in Investigational Drugs

Volumn 7, Issue 1, 2006, Pages 25-32

  Johnston, Tom H ^a   Brotchie, Jonathan M ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b Atuka Ltd   (Canada)

Author keywords

Adenosine A2A; Antiparkinsonian; Monoamine oxidase inhibitors; Non dopaminergic

Indexed keywords

5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 7 (4 METHYL 1 PIPERAZINYL) 2(3H) BENZOXAZOLONE; ADENOSINE A2A RECEPTOR ANTAGONIST; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA SYNUCLEIN; ANTIPARKINSON AGENT; BRASOFENSINE; CEP 1347; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN DERIVATIVE; ETIRACETAM; ISTRADEFYLLINE; LEVODOPA; LEVODOPA METHYL ESTER; LISURIDE; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; NEUROIMMUNOPHILIN; NEUROPROTECTIVE AGENT; NS 2330; PIRIBEDIL; RASAGILINE; REQUIP CR; ROPINIROLE; ROTIGOTINE; SAFINAMIDE; SEP 226330; SUMANIROLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZONISAMIDE;

CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DISEASE COURSE; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; DYSKINESIA; HUMAN; NEUROPROTECTION; PARKINSON DISEASE; PSYCHOSIS; REVIEW; SOMNOLENCE;

ANIMALS; ANTIPARKINSON AGENTS; CLINICAL TRIALS; DRUG DESIGN; DRUG INDUSTRY; HUMANS; MOLECULAR STRUCTURE; PARKINSONIAN DISORDERS;

EID: 30944443720     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Johnston TH, Brotchie JM: Drugs in development for Parkinson's disease. Curr Opin Investig Drugs (2004) 5(7):720-726.
2. Teva Pharmaceutical Ltd: Teva & Lundbeck announce phase III trials did not demonstrate etilevodopa superiority over standard levodopa. Press Release (2003):January 06. www.tevapharm.comp/2003/pr_371.asp
3. Pfizer Inc: Pfizer announces the discontinuation of sumanirole development. Financial Report (2004) July. www.pfizer.com/pfizer/annualreport/2004/financial/print/r6.pdf
4. Sethy VH, Ellerbrock BR, Wu H: U-95666E: A potential antiparkinsonian drug with anxiolytic activity. Prog Neuropsychopharmacol Biol Psychiatry (1997) 21(5):873-883.
5. Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL: Limitations of current Parkinson's disease therapy. Ann Neurol (2003) 53(Suppl 3):S3-S12; discussion S12-S15.
6. DuChane J, Jenkinson C: Changes in quality of life resulting from treatment for persons with advanced Parkinson's disease: Sumanirole versus placebo. International Congress on Parkinson's Disease and Movement Disorders, Miami, FL, USA (2002):P309.
7. Gomez-Mancilla B, Selzer K, Chapman K, Wang M, Simpson S: Sumanirole is a promising new agent in the treatment of Parkinson's disease. International Congress on Parkinson's Disease and Movement Disorders, Miami, FL, USA (2002):P323.
8. Pearce RK, Smith LA, Jackson MJ, Banerji T, Scheel-Kruger J, Jenner P: The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets. Mov Disord (2002) 17(5):877-886.
9. Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P: Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Pharmacol Exp Ther (2002) 303(3):952-958.
10. Shire Pharmaceuticals Inc: Shire: A focused global pharmaceutical company. Focusing on a bright future. Annual Review (2003). www.shire.com/shire/uploads/reports/AR_2003.pdf
11. Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P: The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates. Mov Disord (2004) 19(1):15-21.
12. Neurosearch Inc: NeuroSearch's partner Boehringer Ingelheim has concluded the enrollment of patients in three clinical phase II studies with NS2330 for the treatment of Alzheimer's and Parkinson's diseases. Annual Report (2004):November 09. http://neurosearch.com/pub/pdf/20041109_uk.pdf
13. Sepracor Inc: Therapeutic areas: CNS, SEP-226330. Company Web Site (2005). http://www.sepracor.com/therap/sep226330.html
14. Prestwick Pharmaceuticals Form S1. FORM S-1 (2005):April 22.
15. GlaxoSmithKline Inc: GlaxoSmithKline announces phase III trial of controlled release ropinirole. Press Release (2005):April 12. http://science.gsk.com/pipeline/pipeline-march2005.pdf
16. Stern MB, Marek KL, Friedman J, Hauser RA, LeWitt PA, Tarsy D, Olanow CW: Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord (2004) 19(8):916-923.
17. Lew M, Hauser RA, Hurtig H, Ondo W, Wojcieszek J: Long-term efficacy of rasagiline in Parkinson's disease. Mov Disord (2005) 20:P250.
18. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E: Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): A randomised, doubleblind, parallel-group trial. Lancet (2005) 365(9463):947-954.
19. Parkinson Study Group: A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study. Arch Neurol (2005) 62(2):241-248.
20. Mandel S, Weinreb O, Amit T, Youdim MB: Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev (2005) 48(2):379-387.
21. Hauser RA, Lew M, Hurtig H, Ondo W, Wojcieszek J: Early treatment with rasagiline is more beneficial than delayed treatment start in the long-term management of Parkinson's disease. Mov Disord (2005) 20:P251.
22. Mark MH: Long-term efficacy of istradefylline in patients with advanced Parkinson's disease. Mov Disord (2005) 20:P310.
23. Kyowa Hakko to focus on biotechnology. Pharma Jpn (2004) 1920: P6.
24. Kyowa Hakko Kogyo Co Ltd: Overseas R&D activities. Company World Wide Web Site (2004):November 18.
25. Biogen IDEC Inc: Vernalis and Biogen Idec to collaborate on research for Parkinson's disease. Press Release (2004):June 24. http://biogen.com/news/Biogen/DECPR_045.htm
26. 1A agonist in advanced Parkinson's disease. Mov Disord (2005) 20(8):932-936.
27. EMD Pharmaceuticals: Sarizotan HCI in patients with Parkinson's disease suffering from treatment-associated dyskinesia. (2005):August 01. http://www.clinicaltrials.gov/ct/show/NCT00105508
28. Meco G, Fabrizio E, Epifanio A, Raimondo GD, Vanacore N, Morgante L: Levetiracetam in L-DOPA-induced dyskinesia. Clin Neuropharmacol (2005) 28(2):102-103.
29. Michel A, Ravenscroft P, Hill MP, Bezard E, Crossman AR, Klitgaard H: Seletracetam (UCB 44212) reduces L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. Mov Disord (2005) 20:S102.
30. Meissner W, Hill MP, Tison F, Gross CE, Bezard E: Neuroprotective strategies for Parkinson's disease: Conceptual limits of animal models and clinical trials. Trends Pharmacol Sci (2004) 25(5):249-253.
31. Amgen Inc: Following complete review of phase 2 trial data Amgen confirms decision to halt GDNF study; Comprehensive review of scientific findings, patient safety, drove decision. Press Release (2005):February 11. http://www.amgen.com/media/ media_pr_detail.jsp?year=2005&release/D=673490
32. Lundbeck Inc: Cephalon and Lundbeck announce discontinuation of CEP-1347 clinical trial in Parkinson's disease. Press Release (2005):May 11. http://www.lundbeck.com/investor/releases/ ReleaseDetails/Release_158_EN.asp
33. Novartis AG: Novartis shows dynamic momentum in industry-leading pipeline. Press Release (2005):January 20.
34. Watts R, LeWitt P, Giladi N, Sommerville K, Boroojerdi B: Treatment with rotigotine transdermal system may attenuate progression of disability in patients with early-stage Parkinson's disease. In: Annual Meeting of the American Academy of Neurology, Miami Beach, FL, USA (2005):57.
35. Bartus RT, Emerich D, Snodgrass-Belt P, Fu K, Salzberg-Brenhouse H, Lafreniere D, Novak L, Lo ES, Cooper T, Basile AS: A pulmonary formulation of L-DOPA enhances its effectiveness in a rat model of Parkinson's disease. J Pharmacol Exp Ther (2004) 310(2):828-835.
36. Boston Life Sciences Inc: Boston Life Sciences Inc product pipeline. O-1369, novel DAT blocker for the treatment of Parkinson's disease. Company Web Site (2005):Winter. http://www.bostonlifesciences.com/productpipeline.html
37. Schwarz Pharma Inc: Schwarz Pharma's results exceed expectations. Press Release (2004): February 18. http://cms.schwarzpharma.com/_uploads/assets/ 3268_PR_Preliminary%620Report%202003_e.pdf
38. Almeida L, Vaz-da-Silva M, Silveira P, Falcao A, Maia J, Loureiro A, Torrao L, Machado R, Wright L, Soares-da-Silva P: Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. Clin Neuropharmacol (2004) 27(1):17-24.
39. Watts RL, Raiser CD, Stover NP, Comfeldt ML, Schweikert AW, Allen RC, Subramanian T, Doudet D, Honey CR, Bakay RA: Stereotaxic intrastriatal implantation of human retinal pigment epithelial (hRPE) cells attached to gelatin microcarriers: A potential new cell therapy for Parkinson's disease. J Neural Transm Suppl (2003) 65:215-227.
40. Neurosearch A/S: NeuroSearch's partner Boehringer Ingelheim has concluded the enrollment of patients in three clinical phase II studies with NS2330 for the treatment of Alzheimer's and Parkinson's diseases. Press Release (2004):November 09. http://www.neurosearch.com/pub/pdf/20041109_uk.pdf
41. Chazot PL: Safinamide (Newron Pharmaceuticals). Curr Opin Investig Drugs (2001) 2(6):809-813.
42. Maj R, Fariello RG, Ukmar G, Varasi M, Pevarello P, McArthur RA, Salvati P: PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat. Eur J Pharmacol (1998) 359(1):27-32.
43. Stocchi F, Arnold G, Onofrj M, Kwiecinski H, Szczudlik A, Thomas A, Bonuccelli U, Van Dijk A, Cattaneo C, Sala P, Fariello RG: Improvement of motor function in early Parkinson's disease by safinamide. Neurology (2004) 63(4):746-748.
44. Newron Pharmaceuticals SpA: Newron initiates Parkinson's disease phase III trial with safinamide. Press Release (2004):September 13. http://www.newron.com/press.asp?Action=news&intNewsID=17
45. H Lundbeck A/S: Bifeprunox enters clinical phase III. Press Release (2003):September 02. http://www.lundbeck.com/investor/releases/ReleaseDetails/ Release_105_EN.asp
46. Solvay SA: Parkinson's: Solvay Pharmaceuticals moves SLV 308 compound into phase III clinical development. Press Release (2005):February 03. http://www.solvayhealthcare.co.uk/news/newsitems/ 0,,27259-2-0,00.htm
47. Pharma Inc: Schwarz Pharma's NDA for rotigotine transdermal system is filed by FDA. Press Release (2005):March 29. http://www.schwarzpharma.com/?node_id=2402
48. Servier Inc: Details of adjunct trials for Trivastal (Piribedil). Company Web Site (2005). http://www.servier.com/
49. Gluck MR, Santana LA, Granson H, Yahr MD: Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity. J Neural Transm (2004) 111(6):713-724.
50. Murata M: Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des (2004) 10(6):687-693.
51. Murata M, Horiuchi E, Kanazawa I: Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res (2001) 41(4):397-399.
52. Teva Pharmaceutical Industries Ltd: Teva and Lundbeck announce European approval for AZILECT (rasagiline) 1mg for Parkinson's disease. Press Release (2005):February 22. http://www.tevapharm.com/pr/2005/pr_514.asp
53. Katzenschlager R, Evans A, Manson A, Patsalos PN, Ratnaraj N, Watt H, Timmermann L, Van der Giessen R, Less AJ: Mucuna pruriens in Parkinson's disease: A double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry (2004) 76(12):1672-1677.
54. Manyam BV, Dhanasekaran M, Hare TA: Nouroprotective effects of the antiparkinson drug Mucuna pruriens. Phytother Res (2004) 18(9):706-712.
55. Misra L, Wagner H: Alkaloidal constituents of Mucuna pruriens seeds. Phytochemistry (2004) 66(18):2565-2567.
56. Manyam BV, Dhanasekaran M, Hare TA: Effect of antiparkinson drug HP-200 (Mucuna pruriens) on the central monoaminergic neurotransmitters. Phytother Res (2004) 18(2):97-101.
57. Neurosearch A/S: Neurosearch research and development status May 2005 showing discontinuation of NS-2214. Company Web Site (2005) May. http://www.neurosearch.com/pub/pdf/capitalmarket-RD%20may%202005.pdf
58. Adenosine Therapeutics LLC: Product pipeline for 2005. Company Web Site (2005): March. http://www.adenrx.com/pipe.html
59. Neurocrine Biosciences Inc: Research program for 2005. Company Web Site (2005). http://www.neurocrine.com/html/ res_researchMain.html
60. sanofi-aventis Inc: Development status of central nervous system drugs. Company Web Site (2005):August 31. http://en.sanofi-aventis.com/rd/portfolio/p_rd_portfolio_snc.asp
61. Schering-Plough Corp: Schering-Plough Product pipeline: Worldwide prescription products. Company Web Site (2005):November http://www.sch-plough.com/pdf/productpipeline.pdf
62. 2A receptor antagonist istradefylline in advanced PD. Neurology (2003) 61(3):297-303.
63. 2A receptor antagonists in animal models of Parkinson's disease. Neurology (2003) 61(11 Suppl 6):S55-S61.
64. 2A receptor antagonist treatment of Parkinson's disease. Neurology (2003) 61(3):293-296.
65. Eisai Inc: Two new studies showed Alzheimer's disease treatment beneficial in other types of memory-related conditions. Press Release (2003):April 04. http://www.eisai.com/view_press_release.asp?ID=210&press=67
66. Schneider JS, Pope-Coleman A, Van Velson M, Menzaghi F, Lloyd GK: Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys. Mov Disord (1998) 13(4):637-642.
67. Juvantia Pharma Ltd: Juvantia Pharma announces positive results of phase IIa study in Parkinson's disease. Press Release (2004):June 28. http://www.juvantia.com/eng/news/newsarchive/?nid=35
68. Ivax Corp: Central nervous system: IVAX is developing new drugs to treat diseases of the brain and spinal cord. Company Web Site (2005). http://www.ivax.com/jsps/rd_initiatives/cns.jsp
69. 3 receptor function. Nat Med (2003) 9(6):762-767.
70. Acadia Pharmaceuticals Inc: ACADIA Pharmaceuticals announces encouraging interim results from ongoing phase II trial of ACP-103 for treatment-induced psychosis in patients with Parkinson's disease. Press Release (2005): June 22. http://news.acadia-pharm.com/phoenix.zhtml?c=125180&p=irolnews
71. Acadia Pharmaceuticals Inc: ACADIA Pharmaceuticals announces encouraging interim results from phase II study of ACP-103 in schizophrenia patients with haloperidol-induced akathisia. Press Release (2004):January 12. http://news.acadia-pharm.com/ phoenix.zhtml?c=125180&p=irolnews
72. Eisai Co Ltd: Eisai annual report 2004 describing clinical trial status of E2007. Annual Report (2004). http://www.eisai.co.jp/pdf/eannual/epdf2004an.pdf
73. Oh JD, Bibbiani F, Chase TN: Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Exp Neurol (2002) 177(2):557-564.
74. Katzenschlager R, Manson AJ, Evans A, Watt H, Lees AJ: Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: A double blind cross over study. J Neurol Neurosurg Psychiatry (2004) 75(2):295-297.
75. Panacea Pharmaceuticals Inc: Panacea describe pre-clinical status of PAN-408 and PAN-527. Company Web Site (2005). http://www.panaceapharma.com/technology/parkinson.aspx
76. Dass B, Iravani MM, Huang C, Barsoum J, Engber TM, Galdes A, Jenner P: Sonic hedgehog delivered by an adeno-associated virus protects dopaminergic neurones against 6-OHDA toxicity in the rat. J Neural Transm (2005) 112(6):763-778.
77. IVAX Inc: IVAX laboratories pipeline. A pipeline that spans a wide spectrum. Company Web Site (2005). http://www.ivaxlaboratories.com/jsps/pipeline.jsp
78. 3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Pharmacol Exp Ther (2004) 309(3):1087-1078.
79. Ceregene Inc: Ceregene reports initiation of phase 1 clinical trial of novel gene therapy for patients with Parkinson's disease. PRESS RELEASE (2005): September 21.
80. Migenix Inc: Migenix receives approval to initiate MX-4509 phase I/II study. Press Release (2005): April 28. http://www.migenix.com/newsreleases/042805.pdf
81. Kato H, Araki T, Imai Y, Takahashi A, Itoyama Y: Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease. J Neurol Sci (2003) 208(1-2):9-15.
82. Ono Pharmaceutical Co Ltd: Development status of ONO-2506 for injection/PROGLIA. Press Release (2005):May 26.
83. Phytopharm plc: Commences phase II proof of principle study in Alzheimer's disease. Press Release (2003):December 09.
84. NINDS: NINDS Parkinson's disease neuroprotection trial of CoQ10 and GPI 1485. Press Release (2005):August 01. http://www.clinicaltrials.gov/ct/qui/show/NCT00076492?order=1
85. sanofi-aventis Inc: Molecules of tomorrow: sanofi-aventis describe the clinical trial status of SR 57667. Press Release (2005):November 15. http://en.sanofi-aventis.com/rd/molecules/ p_rd_molecules.asp
86. NINDS: A multi-center, double-blind, pilot study of minocycline and creatine in subjects with early untreated Parkinson's disease. NINDS Parkinson's disease neuroprotection trial (2003):May. http://www.clinicaltrials.gov/ct/show/NCT00063193?order=1
87. Novartis AG: Novartis shows dynamic momentum in industry-leading pipeline. Press Release (2005):January 20.